Serendex held an Extraordinary General Meeting yesterday 9 February 2016. Attached to this notice please find the full minutes from the meeting including the exact results of the shareholders' votes.

149,917,502 shares equivalent to 91.36 % of the share capital of the company were represented at the meeting in person, by proxy or by postal vote.

All items on the agenda were adopted.

Item on agenda Result of shareholders' votes
1 Proposal to authorise the board of directors to carry out one or more capital increases in the Company by way of issue of new shares at a favourable price to one or more new investors of the Company. Votes in favour: 143,960,130
Votes against: 5,957,372
Abstentions: 0
In all: 149,917,502
2 Proposal to authorise the board of directors to carry out one or more capital increases in the Company by way of the issue of new shares at a favourable price with a pre-emption right for the Company's existing shareholders. Votes in favour: 144,610,791
Votes against: 5,262,594
Abstentions: 44,117
In all: 149,917,502
3 Proposal to authorise the board of directors to delist the Company from Oslo Axess within the next six months if the board of directors deems such delisting appropriate. If delisting is effected, the board of directors will apply for deregistration of the Company's shares at VPS. Votes in favour: 147,083,034
Votes against: 2,709,468
Abstentions: 125,000
In all: 149,917,502
4 Proposal to change the registrar keeping the Company's register of shareholders. Votes in favour: 144,684,007
Votes against: 3,933,510
Abstentions: 1,299,985
In all: 149,917,502
5 Proposal to elect former Serendex CFO Søren Bech Justesen as new member of the Board of Directors. Votes in favour: 144,719,107
Votes against: 3,798,410
Abstentions: 1,399,985
In all: 149,917,502

For download Minutes of Serendex extraordinary general meeting

For further information, please contact :

Nadia Vega Vasiljev
Head of Communication and IR
Mobile +45 2014 9615
E-mail: nvv@serendex.com

About Serendex Pharmaceuticals A/S

Serendex Pharmaceuticals develops drugs to treat severe respiratory conditions such as PAP (pulmonary alveolar proteinosis) and ARDS (acute respiratory distress syndrome). These conditions are acute or chronic and have no existing medical treatment. All Serendex drugs are inhaled or induced to the lungs of the patient. This improves the risk/efficacy ratio of the drug and treatment. Serendex has obtained orphan drug designation (ODD) for several indications in both Europe and USA. The company's sole business focus is drug repositioning, i.e. finding new indications and administration routes for existing drugs. Serendex Pharmaceuticals is listed on Oslo Axess. Please visitwww.serendex.com to learn more.

Serendex Pharmaceuticals A/S issued this content on 10 February 2016 and is solely responsible for the information contained herein. Distributed by Public, unedited and unaltered, on 10 February 2016 15:17:31 UTC

Original Document: http://www.serendex.com/minutes-from-serendexs-extraordinary-general-meeting/